Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
There is a need for better visualization of polyps during surveillance endoscopy in patients
with hereditary colon cancer syndromes like Familial Adenomatous Polyposis (FAP) and Lynch
Syndrome (LS), to improve the adenoma detection rate. Optical molecular imaging of adenoma
associated biomarkers is a promising technique to accommodate this need. The biomarker
Vascular Endothelial Growth Factor (VEGF) is overexpressed in adenomatous colon tissue versus
normal tissue and has proven to be a valid target for molecular imaging. The University
Medical Center Groningen (UMCG) developed a fluorescent tracer by labeling the VEGF-targeting
humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the
fluorescent dye IRDye800CW. The investigators hypothesize that when bevacizumab-IRDye800CW is
administered to patients, it accumulates in VEGF expressing adenomas, enabling adenoma
visualization using a newly developed near-infrared (NIR) fluorescence endoscopy platform
(NL43407.042.13). This hypothesis will be tested in this feasibility study, next to the
determination of the optimal tracer dose.